Purpose: The aim of this study was to determine whether surgical resection of the primary tumor contributes to survival in patients with metastatic gastric cancer. Materials and Methods: A total of 288 patients with metastatic gastric cancer from the Akdeniz University, Antalya Training and Research Hospital, and the Meram University of Konya database were retrospectively analyzed. The effect of primary tumor resection on survival of patients with metastatic gastric cancer was investigated using the log-rank test. Kaplan-Meier survival estimates were calculated. Multivariate analysis was performed using Cox proportional hazards regression modeling. Results: The median overall survival was 12.0 months (95% confidence intewrval [CI], 10.4~13.6 months) and 7.8 months (95% CI, 5.5~10.0 months) for patients with and without primary tumor resection, respectively (P<0.001). The median progression-free survival was 8.3 months (95% CI, 7.1~9.5 months) and 6.2 months (95% CI, 5.8~6.7 months) for patients with and without primary tumor resection, respectively (P=0.002). Conclusions: Non-curative gastrectomy in patients with metastatic gastric cancer might increase their survival rate regardless of the occurrence of life-threatening tumor-related complications.
Introduction
Gastric cancer (GC) is one of the most common cancers in the word. Approximately 1 million new cases are diagnosed each year (7.8% of the total number of cancer cases) and half of these cases are diagnosed in East Asia. It is the second leading cause of cancer-related death in the world (738,000 deaths, 9.7% of the total). 1 GC is usually diagnosed at locally advanced or metastatic stages. In untreated stage IV and stage III disease, the life expectancy is 3 and 6 months, respectively. In the presence of peritonitis carcinomatosa, life expectancy is only 2 months. 2 The main curative treatment for GC is the combination of surgery and neoadjuvant chemotherapy, or adjuvant chemotherapy or radiotherapy alone. The higher the stage, the lower the contribution of surgery to survival; for example, the 5-year survival rate in stage I disease with R0 resection is 95% while in stage 2, it is 35% to 65%, depending on the number of lymph nodes involved and dissected. 3 Most GC patients are at an advanced stage and therefore have no chance of curative treatment. 4 The recommendation in the current National Comprehensive Cancer Network guidelines for stage IV GC patients is palliative care including best of care, a clinical study, or chemotherapy. 5 Targeted molecular therapies (such as trastuzumab or bevacizumab) are available in addition to cytotoxic chemo-therapy. 6 Surgical resection in advanced stage disease is required for palliation of tumor-related symptoms such as hemorrhage, obstruction, or perforation. 7 The contribution of palliative surgery to survival has been a question of debate for many years. In our study, we aimed to investigate the effect of non-curative primary tumor resection (PTR)
on survival of patients with metastatic gastric cancer (mGC).
Materials and Methods
Between Statistical analyses were performed using SPSS software ver.
16.0. To determine the properties and compare the patient and tumor characteristics of groups and to perform frequency analysis, chi-square tests and two independent sample t-tests were used. The effect of PTR on OS of patients with mGC was investigated using the log-rank test. Kaplan-Meier survival estimates were calculated. Multivariate analysis was performed using Cox proportional hazards regression modeling. The parameters with P-values <0.15 were included in multivariate analysis. A P-value of <0.05 was considered to be statistically significant.
Results
There was no significant difference between groups regarding age, sex, comorbidity, alcohol consumption, CerbB2 positivity, or second-line chemotherapy (P=0.337, P=0.741, P=0.821, P=0.676, P=0.148, and P=0.428, respectively). All patients received firstline chemotherapy. The characteristics of the groups are shown in Table 1 . While the percentage of patients with a tumor grade 1 or 2 was higher in the PTR (+) group, the percentage of patients with grade 3 was higher in the PTR (-) group (P=0.001).
In addition, the metastatic area was significantly different between groups (P=0.002). No significant pattern in tumor grade or metastatic area was seen in our results (P=0.350; Table 2 ).
The median progression-free survival (PFS) was 8. The median OS was 12.0 months (95% CI, 10.4~13.6 months)
in patients in the PTR (+) group and it was 7.8 months (95% CI, 5.5~10.0 months) in patients in the PTR (-) group (Fig. 2) .
Data on age, sex, comorbidity, smoking, alcohol consumption, grade, CerbB2 status, metastatic area, second-line chemotherapy, and PTR were included in a univariate analysis. Metastatic areas were different between patients who did and did not Values are presented as mean±standard deviation or percent only. CT = computed tomography; N/A = non-applicable. *Classification according to the American Joint Committee on Cancer Grading System.
have PTR (P=0.002). However, all metastatic areas in both patient groups were unfit for surgery. The P-values for these factors are shown in Table 3 and the univariate analysis results are presented in Table 4 . The factors (sex, smoking, grade, CerbB2 status, second-line chemotherapy, and PTR) that had P-values ＜0.15 were included in the multivariate analysis (Table 5 ). In the final multivariate analysis, second-line chemotherapy and PTR were found to be significant (P=0.002 and P=0.005, respectively).
Discussion
In Stage IV GC, one or more areas can be involved, and patients can present with peritoneal metastases, peritoneal malignant fluid cytology, non-regional lymph node metastases, liver metastases, and other organ metastases. In this patient group, the OS rate is 3~5 months with best supportive care and 9~11 months with chemotherapy. 8 If there is human epidermal growth factor receptor-2 overexpression, trastuzumab can be added to the therapy, increasing the survival rate to 11~14 months. Several Japanese studies conducted in East Asia, where half of the annual cases of the disease occur, investigated the effect of tumor burden on palliative surgery. [18] [19] [20] One study demonstrated that peritoneal involvement impairs quality of life but does not affect survival, and that palliative resection shows benefits for survival. 18 Another study with similar results demonstrated that peritoneal metastasis does not have prognostic relevance, and that palliative surgery shows benefits for survival among patients without liver metastases. 19 In another study, the patients were divided into four groups: unresectable tumor, hepatic metastasis, peritoneal metastasis, and distant lymph node metastasis; the it unsuitable for locally advanced and metastatic disease because it delayed chemotherapy. Therefore, it should be limited only to a selected patient group. 21 We examined our data in the context of the ongoing debates and of studies with opposing views on PTR for mGC. In our study, both OS and PFS were longer for patients who had PTR for mGC. However, the most important limitation to our study is that it is of a retrospective design and no data were available on details about the surgery (total or subtotal), surgery related mortality and morbidity, hospital stay, regimens of first and second lines of chemotherapy, or the quality of life of the patients. In addition, patients with grade 1 or 2 tumors had PTR more frequently than patients with grade 3 tumors did. Since patients who did not have surgery were diagnosed through biopsies, some patients may have had insufficient pathological samples for tumor grading. This may have caused a difference in the ratios of grades in both groups, which may be a statistical limitation. To the author's knowledge, this is the first study to demonstrate a possible relationship between grade and PTR in patients with mGC. We also demonstrated that patients who had PTR for mGC received significantly higher rates of second line chemotherapy. We hypothesize that tumor grade could be an important marker for operability in patients with mGC. PTR may be a treatment option to improve PFS and OS results, especially for patients with low-grade tumors.
